Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

In a report released on April 24, Nicolas Pauillac from Kepler Capital maintained a Buy rating on BB Biotech, with a price target of CHF73.00. The ...

Kepler Capital  Sticks to Its Buy Rating for BB Biotech (0JYO)

An announcement from Xenetic Biosciences ( ($XBIO) ) is now available. On April 21, 2026, Xenetic Biosciences, Inc. granted Interim Chief Executive...

Xenetic Biosciences Grants Equity Award to Interim CEO

The latest update is out from Bio-Rad Laboratories ( ($BIO) ). At its April 21, 2026 annual meeting of stockholders, Bio-Rad Laboratories, Inc. rep...

Bio-Rad Laboratories Stockholders Approve Directors and Governance Items

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jade Biosciences (JBIO), Elevance Health (ELV) and...

Analysts Conflicted on These Healthcare Names: Jade Biosciences (JBIO), Elevance Health (ELV) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), Danaher (DHR) and BridgeBio Pharm...

Wall Street Analysts Are Bullish on Top Healthcare Picks

BioVersys AG ( ($CH:BIOV) ) has provided an announcement. BioVersys has completed a mandatory Phase 1 trial of its lead candidate BV100 in healthy ...

BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial

Analysts fell to the sidelines weighing in on BioAge Labs, Inc. (BIOA) and Geron (GERN) with neutral ratings, indicating that the experts are neith...

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Geron (GERN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT) and BioAge Labs, Inc. (BIO...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and BioAge Labs, Inc. (BIOA)

BioVersys AG ( ($CH:BIOV) ) has issued an update. BioVersys has begun patient dosing in its global pivotal Phase 3 RIV-TARGET trial of BV100, an in...

BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia

BioVersys AG ( ($CH:BIOV) ) has shared an update. BioVersys will showcase new clinical and preclinical data on its BV100 and BV500 programs at ESCM...

BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has provided an announcement. MindBio Therapeutics has engaged Venture Liquidity Providers to act as a m...

MindBio Hires Venture Liquidity Providers to Support Market Making on CSE

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on Swedish Orphan Biovitrum AB, with a price target of SEK...

Berenberg Bank Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

An update from Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) is now available. MindBio Therapeutics Corp., a biotechnology company specializing in AI-...

MindBio launches Intox Collect to scale AI-driven intoxication detection

BioVersys AG ( ($CH:BIOV) ) has provided an announcement. BioVersys AG and partners have published pre-clinical data in Nature Communications on Al...

BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential

Biome Australia Ltd ( ($AU:BIO) ) has provided an announcement. Biome Australia Ltd, a specialist in evidence-based probiotics and complementary me...

Biome Australia Appoints New External Auditor Ahead of 2026 AGM

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)....

Analysts’ Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)

In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Buy rating on Ibio, with a price target of $5.00. Nakae covers the Hea...

Ibio (IBIO) Receives a Buy from Chardan Capital

Ibio ( ($IBIO) ) has shared an announcement. On April 8, 2026, iBio announced it had received Clinical Trial Notification acknowledgement from Aust...

iBio Advances to Clinical Stage With IBIO-600 Trial

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Zenas BioPharma, Inc., with a price target of $21.00. Fro...

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

An announcement from BioVersys AG ( ($CH:BIOV) ) is now available. BioVersys AG has convened its 2026 Annual General Meeting of shareholders for Ap...

BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances

BTIG analyst Julian Harrison maintained a Buy rating on Jade Biosciences on April 2 and set a price target of $39.00. The company’s shares closed l...

Jade Biosciences (JBIO) Receives a Rating Update from a Top Analyst

Jade Biosciences ( ($JBIO) ) has provided an announcement. On March 31, 2026, Jade Biosciences, Inc.’s board approved the 2026 Employment Inducemen...

Jade Biosciences Adopts 2026 Employment Inducement Stock Plan

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has issued an update. MindBio Therapeutics has closed an upsized non-brokered private placement, raising...

MindBio Raises $1.44 Million and Launches Marketing Push for Intoxication Detection Tech

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys Technology Corp., a clinical-stage biopharmaceutical company focused on...

BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions

Biome Australia Ltd ( ($AU:BIO) ) has shared an update. Biome Australia Ltd has reported changes to its capital structure following the expiry of a...

Biome Australia Options Lapse Without Exercise, Leaving Share Count Unchanged

BioVersys AG ( ($CH:BIOV) ) has provided an announcement. BioVersys AG has entered an exclusive collaboration and license agreement with U.S. healt...

BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On March 30, 2026, BridgeBio Pharma announced that it had submitted a New Drug Application...

BridgeBio Files NDA for LGMD2I/R9 Oral Therapy

Fortress Biotech ( ($FBIO) ) has issued an update. On March 30, 2026, Fortress Biotech announced that its majority-owned subsidiary Cyprium Therape...

Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital

Insiders have been trading these 5 stocks: (($ASAN)), (($IBIO)), (($RDW)), (($AFL)) and (($SBSW)). Here is a breakdown of their recent trades and t...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$287.84	+2.28%	218.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$287.84	+2.3%	218.79K
3
4
5
6

BIO

BIO

Dividend Overview

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel